Seattle, Jan. 18, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global epinephrine market is estimated to be valued at US$ 2,040 million in 2017, and is projected to exhibit a CAGR of 11.0% over the forecast period (2018 – 2026).
To know the latest trends and insights prevalent in this market, click the link below:
Key Trends and Analysis of the Epinephrine Market:
Market players are focused on adoption of inorganic growth strategy such as merger, acquisition, and collaboration in order to enhance its market share by commercializing its newly approved epinephrine injection in various regions. For instance, in July 2018, Adamis Pharmaceutical Corporation entered into an exclusive distribution and commercialization agreement with Sandoz Inc. Under this agreement, Sandoz will commercialize Adamis’ Symjepi product for emergency treatment of allergic reactions (Type I) including anaphylaxis.
Also, in 2015, Impax Laboratories, Inc., acquired Tower Holdings, Inc., which is the holdings company of Amedra Pharmaceuticals LLC. Amedra is a manufacturer of Adrenaclick (epinephrine injection, USP) auto-injector.
Furthermore, the small companies are engaged in developing novel epinephrine autoinjectors, which provides thermal stability, as the currently available products work optimally at specific temperatures, thereby introducing a lucrative opportunity for players in the global epinephrine market. For instance, Windgap Medical is working on developing a portable device that would mix a dry formulation of the drug into solution, thus providing temperature stability and a long shelf-life of medication for patients suffering from anaphylaxis due to an acute allergy attack.
Also, increase in number of pipeline products is expected to be a major factor boosting the market growth over the forecast period. For instance, in February 2018, Adamis Pharmaceuticals Corporation announced the FDA approval to review the supplemental New Drug Application (sNDA) for its low dose Symjepi product candidate indicated for emergency treatment of anaphylaxis. The low dose version (0.15mg) is intended to potentially treat patients weighing 33-65 pounds.
Key Market Takeaways:
Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: email@example.com